Exenatide and weight loss

Nutrition

Volumn 26, Issue 3, 2010, Pages 243-249

  Bradley, David P ^a   Kulstad, Roger ^b   Schoeller, Dale A ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b MARSHFIELD CLINIC   (United States)

Author keywords

Appetite; Drug treatment; Energy expenditure; Glucagon like peptide 1; Obesity

Indexed keywords

EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INCRETIN; METFORMIN; PLACEBO; SULFONYLUREA;

ANOREXIA; BIOENERGY; CALORIC INTAKE; CLINICAL TRIAL; DOSE RESPONSE; DRUG DEGRADATION; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG RECEPTOR BINDING; ENERGY EXPENDITURE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RELEASE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SATIETY; SIDE EFFECT; STOMACH EMPTYING; WEIGHT REDUCTION;

ANIMALS; DIABETES MELLITUS, TYPE 2; ENERGY INTAKE; ENERGY METABOLISM; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LIZARDS; OBESITY; PEPTIDES; RECEPTORS, GLUCAGON; VENOMS; WEIGHT LOSS;

SQUAMATA;

EID: 75749139750     PISSN: 08999007     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nut.2009.07.008     Document Type: Review

References (53)

1. The International Diabetes Federation. Facts and figures. Did you know? Available at: www.idf.org/home/index.cfm. Accessed July 6, 2009.
2. National Diabetes Information Clearinghouse. National Diabetes Statistics, 2007. Available at: http://diabetes.niddk.nih.gov/DM/PUBS/statistics/#allages. Accessed September 21, 2009.
3. Wild S., Roglic G., Green A., Sicree R., and King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27 (2004) 1047-1053
4. American Diabetes Association. Direct and indirect costs of diabetes in the United States. Available at: www.diabetes.org/diabetes-statistics/cost-of-diabetes-in-us.jsp. Accessed July 4, 2009.
5. The D.C.C.T. Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 (1993) 977-986
6. Stratton I.M., Adler A.I., Neil H.A., Matthews D.R., Mansley S.E., Cull C.A., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321 (2000) 405-412
7. Mokdad A.H., et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 289 (2003) 76-79
8. Kopelman P.G., Caterson I.D., Stock M.J., and Dietz H.W. Clinical obesity in adults and children. 2nd ed. (2005), Blackwell Publishing, Hoboken NJ p. 493
9. Schenk S., Saberi M., and Olefsky J.M. Insulin sensitivity: modulation by nutrients and inflammation. J Clin Invest 118 (2008) 2992-3002
10. Perley M.J., and Kipnis D.M. Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic subjects. J Clin Invest 46 (1967) 1954-1962
11. Nauck M.A., Homberger E., Siegel E.G., Allen R.C., Eaton R.P., Ebert R., et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 63 (1986) 492-498
12. Vilsboll T., Krarup T., Deacon C.F., Madsbad S., and Holst J.J. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 50 (2001) 609-613
13. Holst J.J., and Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab 287 (2004) E199-E206
14. Hawkins D., Bradberry J.C., Cziraky M.J., Talbert R.L., Bartels D.W., and Cerveny J.D. National pharmacy cardiovascular council treatment guidelines for the management of type 2 diabetes mellitus: toward better patient outcomes and new roles for pharmacists. Pharmacotherapy 22 (2002) 436-444
15. U.K. Prospective Diabetes Study Group. U.K. prospective diabetes study 16: overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 44 (1995) 1249-1258
16. Rossetti L., Shulman G.I., Zawalich W., and DeFronzo R.A. Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats. J Clin Invest 80 (1987) 1037-1044
17. McGarry J.D. Banting Lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 51 (2002) 7-18
18. Schwartz J.G., Green G.M., Guan D., McMahan C.A., and Phillips W.T. Rapid gastric emptying of a solid pancake meal in type II diabetic patients. Diabetes Care 19 (1996) 468-471
19. Conarello S.L., Li Z., Ronan J., Roy R.S., Zhu L., Jiang G., et al. Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance. Proc Natl Acad Sci U S A 100 (2003) 6825-6830
20. Buse J.B., Henry R.R., Han J., Kim D.D., Fineman M.S., and Baron A.D. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 27 (2004) 2628-2635
21. DeFronzo R.A., Ratner R., Han J., Kim D., Fineman M.S., and Baron A.D. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes mellitus. Diabetes Care 28 (2005) 1092-1100
22. Kendall D.M., Riddle M.C., Rosenstock J., Zhuang D., Kim D.D., Fineman M.S., et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes mellitus treated with metformin and a sulfonylurea. Diabetes Care 28 (2005) 1083-1091
23. Heine R.J., Van Gaal L.F., Johns D., Mihm M.J., Widel M.H., and Brodows R.G. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 143 (2005) 559-569
24. Blond L. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 8 (2006) 436-447
25. Riddle M.C. Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin. Diabetes Metab Res Rev 22 (2006) 483-491
26. Davis S.N., Johns D., Maggs D., Xu H., Northrup J.H., and Brodows R.G. Exploring the substitution of exenatide for insulin in patients with type 2 diabetes treated with insulin in combination with oral antidiabetes agents. Diabetes Care 30 (2007) 2767-2772
27. Barnett A.H., Burger J., Johns D., Brodows R., Kendall D.M., Roberts A., and Trautmann M.E. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin Ther 29 (2007) 2333-2348
28. Zinman B., Hoogwerf B.J., Duran G.S., Milton D.R., Giaconia J.M., Kim D.D., et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 146 (2007) 477-485
29. Nauck M.A., Duran S., Kim D., Johns D., Northrup J., Festa A., et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 50 (2007) 259-267
30. Henry RR, Ratner RE, Stonehouse AH. Exenatide maintained glycemic control with associated weight reduction over 2 years in patients with type 2 diabetes (abstract 485P). American Diabetes Association, 66th Scientific Sessions, 2006, Washington, DC.
31. The American Heritage dictionary of the English language. 4th ed. (2000), Houghton Mifflin, Boston
32. Edwards C., Stanley S.A., Davis R., Brynes A.E., Frost G., Leighton J.S., et al. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab 281 (2001) E155-E161
33. Verdich C., Flint A., Gutzwiller J.P., Naslund E., Beglinger C., Hellstrom P.M., et al. A meta-analysis of the effect of glucagon-like peptide-1 amide on ad libitum energy intake in humans. J Clin Endocrinol Metab 86 (2001) 4382-4389
34. Schrocchi L.A., Brown T.J., MaClusky N., Brubaker P.L., Auerbach A.B., Joyner A.L., et al. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat Med 2 (1996) 1254-1258
35. Cummings D, Overduin J. Gastrointestinal regulation of food intake. J Clin Invest 2007;117:13-23.
36. Abbott C.R., Monteiro M., Small C.J., Sajedi A., Smith K.L., Parkinson J.R., et al. The inhibitory effects of peripheral administration of peptide YY(3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway. Brain Res 1044 (2005) 127-131
37. Horowitz M., Dent J., Fraser R., Sun W., and Hebbard G. Role and integration of mechanisms controlling gastric emptying. Dig Dis Sci 39 suppl (1994) 7S-13
38. Phillips W.T., Schwartz J.G., and McMahan C.A. Rapid gastric emptying of an oral glucose solution in type 2 diabetic patients. J Nucl Med 33 (1992) 1496-1500
39. Horowitz M., and Fraser R. Disordered gastric motor function in diabetes mellitus. Diabetologia 37 (1994) 543-551
40. Uttenthal L.O., and Blazquez E. Characterization of high-affinity receptors for truncated glucagon-like peptide-1 in rat gastric glands. FEBS Lett 262 (1990) 139-141
41. Drucker D.J., and Asa S. Glucagon gene expression in vertebrate brain. J Biol Chem 263 (1998) 13475-13478
42. Shughrue P.J., Lane M.V., and Merchenthaler I. Glucagon-like peptide-1 receptor (GLP1-R) mRNA in the rat hypothalamus. Endocrinology 137 (1996) 5159-5162
43. Schick R.R., Zimmermann J.P., vorm Walde T., and Schusdziarra V. Peptides that regulate food intake: glucagon-like peptide 1-(7-36) amide acts at lateral and medial hypothalamic sites to suppress feeding in rats. Am J Physiol Regul Integr Comp Physiol 284 (2003) R1427-R1435
44. Flint A., Raben A., Astrup A., and Holst J.J. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 101 (1998) 515-520
45. Pérez-Tilve D., González-Matías L., Alvarez-Crespo M., Leiras R., Tovar S., Diéguez C., et al. Exendin-4 potently decreases ghrelin levels in fasting rats. Diabetes 56 (2007) 143-151
46. Shalev A., Holst J.J., and Keller U. Effects of glucagon-like peptide 1 (7-26 amide) on whole-body protein metabolism in healthy man. Curr Opin Endocrinol Diabetes Obesity 27 (1997) 10-16
47. Flint A., Raben A., Ersboll A.K., Holst J.J., and Astrup A. The effect of glucagon-like peptide-1 on energy expenditure and substrate metabolism in humans. Int J Obes Relat Metab Disord 24 (2000) 288-289
48. Flint A., Raben A., Ersboll A.K., Holst J.J., and Astrup A. The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. Int J Obes Relat Metab Disord 25 (2001) 781-792
49. Pannacciulli N., Bunt J., Koska J., Borgadus C., and Krakoff J. Higher fasting plasma concentrations of glucagon-like peptide 1 are associated with higher resting energy expenditure and fat oxidation rates in humans. Am J Clin Nutr 84 (2006) 556-560
50. Gutzwiller J.P., Drewe J., Göke B., Schmidt H., Rohrer B., Lareida J., and Beglinger C. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol 267 (1999) R1541-R1544
51. Toft-Nielsen M.B., Madsbad S., and Holst J.J. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care 22 (1999) 1137-1143
52. Hellström P.M., and Näslund E. Role of GLP-1 in meal taking. Appetite 32 (1999) 276
53. Zander M., Taskiran M., Toft-Nielsen M.B., Madsbad S., and Holst J.J. Additive glucose-lowering effects of glucagon-like peptide-1 and metformin in type 2 diabetes. Diabetes Care 24 (2001) 720-725